Cutaneous Oncology News

Researchers at Massachusetts General Hospital have discovered a skin pigment mechanism that could be developed into a topical drug aimed at reducing skin cancer risk, according to a study published in Cell.

A novel technique of low-dose rotational total skin electron beam therapy provided a fast and durable response in a small cohort of patients with skin lesions associated with cutaneous T-cell lymphoma.

The FDA granted priority review to pembrolizumab for adjuvant treatment of certain patients with high-risk melanoma.

The FDA granted fast track designation to nemvaleukin alfa for treatment of mucosal melanoma.

While melanoma incidence and prevalence in the U.S. increased between 1990 and 2019, mortality rates remained stable over that time, according to findings from a mathematical model.

A pediatric melanoma registry developed at St. Jude Children’s Research Hospital has helped researchers improve the classification of pediatric melanocytic tumors.

Tissue-rearranging reconstruction is needed more in melanomas of the head and neck, which have high local recurrence rates, compared with keratinocyte carcinomas, according to a study.

Overall survival was lower for patients with early-stage cutaneous T-cell lymphoma who had low-level blood involvement, according to a study.

Metformin, even in low doses, may be associated with a decreased risk for basal cell carcinoma, according to a study.

The FDA expanded the approval of pembrolizumab to include treatment of patients with locally advanced cutaneous squamous cell carcinoma not curable by surgery or radiation, according to the agent’s manufacturer.